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Background
Debilitating neurodegenerative disorders (NDs) includ-
ing Alzheimer’s disease, Parkinson’s disease, and poly-
glutamine diseases are a major public health challenge
in increasingly aging societies. Currently approved thera-
peutics are successful in slowing the progression of NDs
but not in reversing or preventing the symptoms of
NDs. The simplicity and amenability of the nematode
Caenorhabditis elegans (C. elegans) to high-throughput
genomic, proteomic and drug screening approaches
make this organism an attractive choice for identifying
new therapeutic compounds for these disorders and for
understanding their mechanism of action. Indeed, a
diverse set of informative C. elegans ND models have
been developed manifesting abnormal behavioural or
pathological phenotypes that partially recapitulate the
salient cellular, molecular and pathological aspects of
several distinct human NDs processes. Recent studies
have identified dnajc5 encoding cysteine-string protein
a (CSPa) as the disease-causing gene of a rare autosomal
dominant human ND known as adult-onset neuronal
ceroid lipofuscinosis (ANCL). The null animal models of
CSP are characterised by impaired neurotransmission,
pre-synaptic neurodegeneration and premature mortality.
Simple model organisms may therefore shed light on
potential therapeutic approaches for ANCL and other
NDs.
Materials and methods
In this study, we are integrating multiple well-defined
C. elegans ND models to uncover potential therapeutic
interventions that target shared pathogenic pathways.
We tested parameters such as locomotion and lifespan
which act as a measure of neurological and neuromuscu-
lar function, and viability upon drug treatment in C.
elegans.
Results
Using locomotion behaviour and lifespan as phenotypic
readouts, we uncovered the anticonvulsant ethosuximide
as a promising candidate drug that not only rescues the
short lifespan of a C. elegans null mutant model of ANCL,
but also ameliorates the mobility defect and short lifespan
of a distinct worm tauopathy model based on transgenic
expression of mutant human tau. We are currently investi-
gating how ethosuximide might exert its neuroprotective
properties. We found that ethosuximide has no obvious
aggregation-suppressing effect and suppression of proteo-
toxicity by ethosuximide is independent of the low voltage
activated T-type calcium channel, the principal therapeutic
target of ethosuximide in controlling generalised absence
epilepsy.
Conclusions
Overall, our data provide good evidence that anti-epileptic
ethosuximide is efficacious in several worm ND models.
Further investigation of its precise mode of action and
validation in vertebrate systems is required to gauge the
effectiveness of this compound as early leads for drug dis-
covery. These findings should encourage further screening
and characterisation of other neuroprotective compounds,
and ultimately may assist in accelerating the clinical eva-
luation and development of drugs to combat protein con-
formational disorders in general.
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